Trade ZNTL anytime, even after market hours
Regulated by
MAS
Trusted by
400,000+ users
Zentalis Pharmaceuticals, Inc. (ZNTL) is trading at US$4.07, up 1.98% today as of Sep 8, 14:12 EDT. The company has a market capitalisation of US$362.12M. Over the past 52 weeks, ZNTL has traded between US$1.21 and US$6.95. On Syfe you can trade ZNTL with $0 commission and add it to your watchlist.
| Previous close | US$3.99 |
|---|---|
| Market cap | US$362.12M |
| 52-week range | US$1.21 – US$6.95 |
| Volume | 1M |
| Exchange | US |
Add to Watchlist
Set Price Alert
Zentalis Pharmaceuticals, Inc.
Zentalis Pharmaceuticals, Inc. is a clinical oncology innovator developing an oral, non-chemotherapy, biomarker-driven treatment approach for ovarian cancer and multiple tumor types. The therapeutics development and biomarker expertise is advancing monotherapy and combination studies of its investigational potential first-in-class WEE1 inhibitor, azenosertib. It is focused on translating WEE1 science into clinical practice, aiming to equip physicians with a targeted, orally available medicine that enhances treatment experience, choice, and outcomes. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.
Year: 2020
Zentalis Pharmaceuticals, Inc. (ZNTL) stock is trading at US$4.07, +1.98% from the previous close of US$3.99.
The market cap for Zentalis Pharmaceuticals, Inc. (ZNTL) stock is approximately US$362.12M.
The 52-week high for Zentalis Pharmaceuticals, Inc. (ZNTL) stock is US$6.95.
The 52-week low for Zentalis Pharmaceuticals, Inc. (ZNTL) stock is US$1.21.
Zentalis Pharmaceuticals, Inc. (ZNTL) does not currently pay a dividend.
Stay on top of ZNTL
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
